Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoCellular Therapeutics Ltd (NYSE MKT LLC:IMUC)

Delayed Data
As of Feb 08
 -0.0063 / -2.81%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. The company was founded by John S. Yu on March 20, 1987 and is headquartered in Calabasas, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
23622 Calabasas Road
Calabasas California 91302
P:(818) 264-2300
Investor Relations:



Other institutional9.55%
Mutual fund holders3.73%
Individual stakeholders1.62%

Top Executives

Andrew GengosPresident, Chief Executive Officer & Director
David E. FractorChief Accounting Officer & Vice President-Finance
Steven J. SwansonSenior Vice President-Research
John S. YuSecretary & Director
Anthony J. GringeriSenior Vice President-Strategic Resources